Literature DB >> 3823720

Esophagitis in the immunocompromised host: role of esophagoscopy in diagnosis.

R R Wheeler, J E Peacock, J M Cruz, J E Richter.   

Abstract

Thirty episodes of presumed infectious esophagitis in immunocompromised patients were investigated by means of esophagoscopy. Indications for esophagoscopy included dysphagia, odynophagia, and retrosternal pain. Factors potentially predisposing patients to esophagitis included previous exposure to radiation, recent cytotoxic chemotherapy, recent antibiotic therapy, corticosteroid therapy, and neutropenia. Sixteen of the 18 barium esophagograms done before esophagoscopy was performed revealed abnormalities; in 14 cases the results were consistent with infectious esophagitis. Abnormalities were noted during 27 of 30 esophagoscopy procedures. Visual findings were consistent with candidal esophagitis in 18 cases, with viral esophagitis in four, and with both in one. Specific infectious diagnoses were established by culture or histology in 17 episodes: 12 of candidal esophagitis, two of herpes simplex esophagitis, two of concomitant candidal and herpetic esophagitis, and one of enteroviral esophagitis. Specific noninfectious diagnoses were made in two episodes, and the esophagus was found to be normal in three. No specific diagnosis was made in eight episodes although visual examination indicated the presence of esophagitis. The only postesophagoscopy complications recorded were isolated episodes of spiking fever in three patients. In this compromised-host population with presumed infectious esophagitis, esophagoscopy resulted in a rapid and specific infectious diagnosis in 57% of episodes.

Entities:  

Mesh:

Year:  1987        PMID: 3823720     DOI: 10.1093/clinids/9.1.88

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  8 in total

1.  T-cell populations in liver and renal transplant recipients with infectious esophagitis.

Authors:  D E Brouillette; J Alexander; Y K Yoo; M C Chien; R E Tarter; J Gavaler; D H Van Thiel
Journal:  Dig Dis Sci       Date:  1989-01       Impact factor: 3.199

2.  Infectious esophagitis following liver and renal transplantation.

Authors:  J A Alexander; D E Brouillette; M C Chien; Y K Yoo; R E Tarter; J S Gavaler; D H Van Thiel
Journal:  Dig Dis Sci       Date:  1988-09       Impact factor: 3.199

3.  Endoscopy in patients receiving radiation therapy to the thorax.

Authors:  Rodney A Perez; Dayna S Early
Journal:  Dig Dis Sci       Date:  2002-01       Impact factor: 3.199

Review 4.  Invasive oesophageal candidiasis: current and developing treatment options.

Authors:  Jose A Vazquez
Journal:  Drugs       Date:  2003       Impact factor: 9.546

5.  Incidence and outcome of overt gastrointestinal bleeding in patients undergoing bone marrow transplantation.

Authors:  S Kaur; G Cooper; S Fakult; H M Lazarus
Journal:  Dig Dis Sci       Date:  1996-03       Impact factor: 3.199

6.  Long-Term Trends in Esophageal Candidiasis Prevalence and Associated Risk Factors with or without HIV Infection: Lessons from an Endoscopic Study of 80,219 Patients.

Authors:  Yuta Takahashi; Naoyoshi Nagata; Takuro Shimbo; Takeshi Nishijima; Koji Watanabe; Tomonori Aoki; Katsunori Sekine; Hidetaka Okubo; Kazuhiro Watanabe; Toshiyuki Sakurai; Chizu Yokoi; Masao Kobayakawa; Hirohisa Yazaki; Katsuji Teruya; Hiroyuki Gatanaga; Yoshimi Kikuchi; Sohtaro Mine; Toru Igari; Yuko Takahashi; Akio Mimori; Shinichi Oka; Junichi Akiyama; Naomi Uemura
Journal:  PLoS One       Date:  2015-07-24       Impact factor: 3.240

7.  Factors associated with esophageal candidiasis and its endoscopic severity in the era of antiretroviral therapy.

Authors:  So Nishimura; Naoyoshi Nagata; Takuro Shimbo; Naoki Asayama; Junichi Akiyama; Norio Ohmagari; Hirohisa Yazaki; Shinichi Oka; Naomi Uemura
Journal:  PLoS One       Date:  2013-03-26       Impact factor: 3.240

8.  Candidemia in immunocompromised and immunocompetent critically ill patients: a prospective comparative study.

Authors:  G Dimopoulos; A Karabinis; G Samonis; M E Falagas
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-06       Impact factor: 3.267

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.